Ifosfamide
- Generic Name
- Ifosfamide
- Brand Names
- Ifex
- Drug Type
- Small Molecule
- Chemical Formula
- C7H15Cl2N2O2P
- CAS Number
- 3778-73-2
- Unique Ingredient Identifier
- UM20QQM95Y
- Background
Ifosfamide is a chemotherapeutic agent chemically related to the nitrogen mustards and a synthetic analog of cyclophosphamide. It is active as an alkylating agent and an immunosuppressive agent.
- Indication
Used as a component of various chemotherapeutic regimens as third-line therapy for recurrent or refractory germ cell testicular cancer. Also used as a component of various chemotherapeutic regimens for the treatment of cervical cancer, as well as in conjunction with surgery and/or radiation therapy in the treatment of various soft tissue sarcomas. Other indications include treatment of osteosarcoma, bladder cancer, ovarian cancer. small cell lung cancer, and non-Hodgkin's lymphoma.
- Associated Conditions
- Bladder Cancer, Cervical Cancer, Ewing's Sarcoma, Head And Neck Cancer, Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma (NHL), Osteosarcoma, Ovarian Cancer, Pancreatic Cancer, Small Cell Lung Cancer (SCLC), Soft Tissue Sarcoma, Testicular Germ Cell Cancer, Thymoma
- Associated Therapies
- -
Combination Chemotherapy and Radiation Therapy With or Without Methotrexate in Treating Young Patients With Newly Diagnosed Gliomas
- First Posted Date
- 2006-01-18
- Last Posted Date
- 2013-12-19
- Target Recruit Count
- 150
- Registration Number
- NCT00278278
- Locations
- 🇺🇸
M. D. Anderson Cancer Center at University of Texas, Houston, Texas, United States
Observation and/or Combination Chemotherapy After Surgery or Biopsy in Treating Young Patients With Extracranial Germ Cell Tumors
- Conditions
- First Posted Date
- 2006-01-11
- Last Posted Date
- 2013-09-17
- Lead Sponsor
- Children's Cancer and Leukaemia Group
- Target Recruit Count
- 105
- Registration Number
- NCT00274950
- Locations
- 🇬🇧
Addenbrooke's Hospital, Cambridge, England, United Kingdom
🇬🇧Birmingham Children's Hospital, Birmingham, England, United Kingdom
🇬🇧Leicester Royal Infirmary, Leicester, England, United Kingdom
Rituximab and Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Non-Hodgkin's Lymphoma
- First Posted Date
- 2006-01-11
- Last Posted Date
- 2023-06-29
- Lead Sponsor
- Eastern Cooperative Oncology Group
- Target Recruit Count
- 100
- Registration Number
- NCT00274924
- Locations
- 🇺🇸
Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago, Illinois, United States
🇺🇸Mason District Hospital, Havana, Illinois, United States
🇺🇸Greater Baltimore Medical Center Cancer Center, Baltimore, Maryland, United States
Evaluate PKs and Efficacy Assessment of Palifermin in Patients With Sarcoma
- Conditions
- Interventions
- First Posted Date
- 2005-12-20
- Last Posted Date
- 2012-05-16
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 49
- Registration Number
- NCT00267046
- Locations
- 🇺🇸
U.T.M.D. Anderson Cancer Center, Houston, Texas, United States
Combination Chemotherapy and Radiation Therapy in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Relapsed or Refractory Hodgkin's Lymphoma
- First Posted Date
- 2005-11-21
- Last Posted Date
- 2016-02-01
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 98
- Registration Number
- NCT00255723
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Samarium Sm 153 and Stem Cell Transplant Followed By Radiation Therapy Patients With Osteosarcoma
- First Posted Date
- 2005-10-27
- Last Posted Date
- 2020-03-10
- Target Recruit Count
- 11
- Registration Number
- NCT00245011
- Locations
- 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
High-dose Chemotherapy With Autologous Stem Cell Transplantation in Poor Prognosis Germ-cell Tumors: TAXIF II
- First Posted Date
- 2005-10-04
- Last Posted Date
- 2011-02-25
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 50
- Registration Number
- NCT00231582
- Locations
- 🇫🇷
Hôpital TENON, Service d'Oncologie Médicale, Paris, France
Adjuvant Radiation Therapy With Ifosfamide in Patients With Mixed Mesodermal Tumors of the Uterus
- Conditions
- Interventions
- First Posted Date
- 2005-10-04
- Last Posted Date
- 2019-01-23
- Lead Sponsor
- Montefiore Medical Center
- Target Recruit Count
- 30
- Registration Number
- NCT00231842
- Locations
- 🇺🇸
Montefiore Medical Center, Bronx, New York, United States
Neoadjuvant Adriamycin and Ifosfamide Plus High-Dose ICE in Patients With Soft Tissue Sarcoma (STS)
- Conditions
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2007-04-20
- Lead Sponsor
- University Hospital Tuebingen
- Registration Number
- NCT00204646
- Locations
- 🇩🇪
Medical Center II, University of Tuebingen, Tuebingen, Germany
German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (05/93)
- Conditions
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2023-03-17
- Lead Sponsor
- Goethe University
- Target Recruit Count
- 720
- Registration Number
- NCT00199069
- Locations
- 🇩🇪
University Hospital, Medical Dept. II, Frankfurt, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.